NCT00492401View on ClinicalTrials.gov

Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

October 31, 2014

Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Secondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG

decitabine

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

OTHER

high performance liquid chromatography

Correlative studies

GENETIC

microarray analysis

Correlative studies

GENETIC

RNA analysis

Correlative studies

OTHER

mass spectrometry

Correlative studies

GENETIC

DNA methylation analysis

Correlative studies

OTHER

matrix-assisted laser desorption/ionization time of flight mass spectrometry

Correlative studies

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00492401 - Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter